Review



anti nfκb p65 p s536 antibody  (Bioss)


Bioz Verified Symbol Bioss is a verified supplier
Bioz Manufacturer Symbol Bioss manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Bioss anti nfκb p65 p s536 antibody
    OMVs upregulate tumor MHC I expression via the TLR4–NF‐κB–NLRC5 axis. (A) Relative mRNA expression of H‐2K and H‐2D in B16 cells after 24 h treatment with different OMV concentrations. (B) Representative plots for flow cytometry analysis of MHC‐I⁺ B16 tumor cell. (C) Proportions of MHC I + B16 cells after indicated treatments. (D) Volcano plot of differentially expressed genes in OMV versus control groups (red: significantly upregulated ≥2‐fold; blue: significantly downregulated ≥2‐fold). (E) GO enrichment of upregulated genes. (F) KEGG pathway enrichment of genes associated with innate and adaptive immune responses. (G‐H) Heat maps of MHC I–related genes detected by RNA‐seq (G) and qPCR (H). (I) Western blot analysis of TLR4 (≈100 kDa), <t>p‐p65</t> (≈70 kDa), NLRC5 (≈225 kDa), and β‐actin (≈48 kDa) in tumor cells. (J) Proportions of MHC I + tumor cells after indicated treatments. (K) Proposed mechanism of OMV‐induced MHC I upregulation through the TLR–NF‐κB–NLRC5 pathway. Created in BioRender. Zhang, F. (2026) https://BioRender.com/97sw6s6 . Data are mean ± SD (n = 3). Statistical significance was determined using Student's t‐test or One‐way ANOVA. **** p < 0.0001.
    Anti Nfκb P65 P S536 Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 95/100, based on 153 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+nf%CE%BAb+p65/NFKB+p65(Ser536)+Polyclonal+Antibody/pmc13672686-210-8-25
    Average 95 stars, based on 153 article reviews
    anti nfκb p65 p s536 antibody - by Bioz Stars, 2026-11
    95/100 stars

    Images

    1) Product Images from "Intratumoral Fusogenic Outer Membrane Vesicles Enhance Antitumor Immunity Through Tumor MHC‐I Upregulation and Tumor Bacterization"

    Article Title: Intratumoral Fusogenic Outer Membrane Vesicles Enhance Antitumor Immunity Through Tumor MHC‐I Upregulation and Tumor Bacterization

    Journal: Advanced Science

    doi: 10.1002/advs.78279

    OMVs upregulate tumor MHC I expression via the TLR4–NF‐κB–NLRC5 axis. (A) Relative mRNA expression of H‐2K and H‐2D in B16 cells after 24 h treatment with different OMV concentrations. (B) Representative plots for flow cytometry analysis of MHC‐I⁺ B16 tumor cell. (C) Proportions of MHC I + B16 cells after indicated treatments. (D) Volcano plot of differentially expressed genes in OMV versus control groups (red: significantly upregulated ≥2‐fold; blue: significantly downregulated ≥2‐fold). (E) GO enrichment of upregulated genes. (F) KEGG pathway enrichment of genes associated with innate and adaptive immune responses. (G‐H) Heat maps of MHC I–related genes detected by RNA‐seq (G) and qPCR (H). (I) Western blot analysis of TLR4 (≈100 kDa), p‐p65 (≈70 kDa), NLRC5 (≈225 kDa), and β‐actin (≈48 kDa) in tumor cells. (J) Proportions of MHC I + tumor cells after indicated treatments. (K) Proposed mechanism of OMV‐induced MHC I upregulation through the TLR–NF‐κB–NLRC5 pathway. Created in BioRender. Zhang, F. (2026) https://BioRender.com/97sw6s6 . Data are mean ± SD (n = 3). Statistical significance was determined using Student's t‐test or One‐way ANOVA. **** p < 0.0001.
    Figure Legend Snippet: OMVs upregulate tumor MHC I expression via the TLR4–NF‐κB–NLRC5 axis. (A) Relative mRNA expression of H‐2K and H‐2D in B16 cells after 24 h treatment with different OMV concentrations. (B) Representative plots for flow cytometry analysis of MHC‐I⁺ B16 tumor cell. (C) Proportions of MHC I + B16 cells after indicated treatments. (D) Volcano plot of differentially expressed genes in OMV versus control groups (red: significantly upregulated ≥2‐fold; blue: significantly downregulated ≥2‐fold). (E) GO enrichment of upregulated genes. (F) KEGG pathway enrichment of genes associated with innate and adaptive immune responses. (G‐H) Heat maps of MHC I–related genes detected by RNA‐seq (G) and qPCR (H). (I) Western blot analysis of TLR4 (≈100 kDa), p‐p65 (≈70 kDa), NLRC5 (≈225 kDa), and β‐actin (≈48 kDa) in tumor cells. (J) Proportions of MHC I + tumor cells after indicated treatments. (K) Proposed mechanism of OMV‐induced MHC I upregulation through the TLR–NF‐κB–NLRC5 pathway. Created in BioRender. Zhang, F. (2026) https://BioRender.com/97sw6s6 . Data are mean ± SD (n = 3). Statistical significance was determined using Student's t‐test or One‐way ANOVA. **** p < 0.0001.

    Techniques Used: Expressing, Flow Cytometry, Analysis, Control, RNA Sequencing, Western Blot

    Related Articles

    other:

    Article Title: Carvacrol alleviates endoplasmic reticulum stress and inflammation induced by lipopolysaccharide by enhancing endoplasmic reticulum autophagy in dairy mammary epithelial cells.
    Article Snippet: The proteins were resolved by SDS-PAGE, and then transferred to polyvinylidene difluoride membranes. p-IκB (1:1,000, bs2513R, Bioss), IκB (1:5,000, 10268–1-AP, proteintech), NFκB p65 (1:2,000, 10745–1-AP, proteintech), p-NFκB p65 (1:500, bs-0982R, Bioss), LC3B (1:1,000, T5599, Abmart), p62 (1:5,000, 66184–1-Ig, proteintech), CHOP (1:2,000, 15204–1-AP, proteintech), GRP78 (1:2,000, 11587–1-AP, proteintech), p-IRE1α (1:2,000, AF7150, Affinity), IRE1α (1:2,000, 27528–1-AP, proteintech), PERK (1:2,000, 20582–1-AP, proteintech), p-PERK (1:2,000, 29546–1-AP, proteintech), ATF6 (1:2,000, 24169–1-AP, proteintech), FAM134B (1:2,000, 21537– 1-AP, proteintech), TEX264 (1:2,000, 25858–1-AP, proteintech), ATL3 (1:2,000, 16921–1-AP, proteintech), SEC62 (1:2,000, bs-19619R, Bioss), β-actin (1:20,000, 66009–1-Ig, proteintech).



    Similar Products

    95
    Bioss anti nfκb p65 p s536 antibody
    OMVs upregulate tumor MHC I expression via the TLR4–NF‐κB–NLRC5 axis. (A) Relative mRNA expression of H‐2K and H‐2D in B16 cells after 24 h treatment with different OMV concentrations. (B) Representative plots for flow cytometry analysis of MHC‐I⁺ B16 tumor cell. (C) Proportions of MHC I + B16 cells after indicated treatments. (D) Volcano plot of differentially expressed genes in OMV versus control groups (red: significantly upregulated ≥2‐fold; blue: significantly downregulated ≥2‐fold). (E) GO enrichment of upregulated genes. (F) KEGG pathway enrichment of genes associated with innate and adaptive immune responses. (G‐H) Heat maps of MHC I–related genes detected by RNA‐seq (G) and qPCR (H). (I) Western blot analysis of TLR4 (≈100 kDa), <t>p‐p65</t> (≈70 kDa), NLRC5 (≈225 kDa), and β‐actin (≈48 kDa) in tumor cells. (J) Proportions of MHC I + tumor cells after indicated treatments. (K) Proposed mechanism of OMV‐induced MHC I upregulation through the TLR–NF‐κB–NLRC5 pathway. Created in BioRender. Zhang, F. (2026) https://BioRender.com/97sw6s6 . Data are mean ± SD (n = 3). Statistical significance was determined using Student's t‐test or One‐way ANOVA. **** p < 0.0001.
    Anti Nfκb P65 P S536 Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+nf%CE%BAb+p65/NFKB+p65(Ser536)+Polyclonal+Antibody/pmc13672686-210-8-25
    Average 95 stars, based on 1 article reviews
    anti nfκb p65 p s536 antibody - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology p nf ĸb p65
    OMVs upregulate tumor MHC I expression via the TLR4–NF‐κB–NLRC5 axis. (A) Relative mRNA expression of H‐2K and H‐2D in B16 cells after 24 h treatment with different OMV concentrations. (B) Representative plots for flow cytometry analysis of MHC‐I⁺ B16 tumor cell. (C) Proportions of MHC I + B16 cells after indicated treatments. (D) Volcano plot of differentially expressed genes in OMV versus control groups (red: significantly upregulated ≥2‐fold; blue: significantly downregulated ≥2‐fold). (E) GO enrichment of upregulated genes. (F) KEGG pathway enrichment of genes associated with innate and adaptive immune responses. (G‐H) Heat maps of MHC I–related genes detected by RNA‐seq (G) and qPCR (H). (I) Western blot analysis of TLR4 (≈100 kDa), <t>p‐p65</t> (≈70 kDa), NLRC5 (≈225 kDa), and β‐actin (≈48 kDa) in tumor cells. (J) Proportions of MHC I + tumor cells after indicated treatments. (K) Proposed mechanism of OMV‐induced MHC I upregulation through the TLR–NF‐κB–NLRC5 pathway. Created in BioRender. Zhang, F. (2026) https://BioRender.com/97sw6s6 . Data are mean ± SD (n = 3). Statistical significance was determined using Student's t‐test or One‐way ANOVA. **** p < 0.0001.
    P Nf ĸb P65, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+nf%CE%BAb+p65/p-NF%CE%BAB+p65+Antibody/pm42874730-142-24-30
    Average 96 stars, based on 1 article reviews
    p nf ĸb p65 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology p p65
    OMVs upregulate tumor MHC I expression via the TLR4–NF‐κB–NLRC5 axis. (A) Relative mRNA expression of H‐2K and H‐2D in B16 cells after 24 h treatment with different OMV concentrations. (B) Representative plots for flow cytometry analysis of MHC‐I⁺ B16 tumor cell. (C) Proportions of MHC I + B16 cells after indicated treatments. (D) Volcano plot of differentially expressed genes in OMV versus control groups (red: significantly upregulated ≥2‐fold; blue: significantly downregulated ≥2‐fold). (E) GO enrichment of upregulated genes. (F) KEGG pathway enrichment of genes associated with innate and adaptive immune responses. (G‐H) Heat maps of MHC I–related genes detected by RNA‐seq (G) and qPCR (H). (I) Western blot analysis of TLR4 (≈100 kDa), <t>p‐p65</t> (≈70 kDa), NLRC5 (≈225 kDa), and β‐actin (≈48 kDa) in tumor cells. (J) Proportions of MHC I + tumor cells after indicated treatments. (K) Proposed mechanism of OMV‐induced MHC I upregulation through the TLR–NF‐κB–NLRC5 pathway. Created in BioRender. Zhang, F. (2026) https://BioRender.com/97sw6s6 . Data are mean ± SD (n = 3). Statistical significance was determined using Student's t‐test or One‐way ANOVA. **** p < 0.0001.
    P P65, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+nf%CE%BAb+p65/p-NF%CE%BAB+p65+Antibody/pm42830147-100-10-15
    Average 96 stars, based on 1 article reviews
    p p65 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    86
    Wanleibio anti p nfκb p65 ser536 rabbit pab
    OMVs upregulate tumor MHC I expression via the TLR4–NF‐κB–NLRC5 axis. (A) Relative mRNA expression of H‐2K and H‐2D in B16 cells after 24 h treatment with different OMV concentrations. (B) Representative plots for flow cytometry analysis of MHC‐I⁺ B16 tumor cell. (C) Proportions of MHC I + B16 cells after indicated treatments. (D) Volcano plot of differentially expressed genes in OMV versus control groups (red: significantly upregulated ≥2‐fold; blue: significantly downregulated ≥2‐fold). (E) GO enrichment of upregulated genes. (F) KEGG pathway enrichment of genes associated with innate and adaptive immune responses. (G‐H) Heat maps of MHC I–related genes detected by RNA‐seq (G) and qPCR (H). (I) Western blot analysis of TLR4 (≈100 kDa), <t>p‐p65</t> (≈70 kDa), NLRC5 (≈225 kDa), and β‐actin (≈48 kDa) in tumor cells. (J) Proportions of MHC I + tumor cells after indicated treatments. (K) Proposed mechanism of OMV‐induced MHC I upregulation through the TLR–NF‐κB–NLRC5 pathway. Created in BioRender. Zhang, F. (2026) https://BioRender.com/97sw6s6 . Data are mean ± SD (n = 3). Statistical significance was determined using Student's t‐test or One‐way ANOVA. **** p < 0.0001.
    Anti P Nfκb P65 Ser536 Rabbit Pab, supplied by Wanleibio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+nf%CE%BAb+p65/anti+nf+p65+%CE%BAb/pmc13169578-12-0-6
    Average 86 stars, based on 1 article reviews
    anti p nfκb p65 ser536 rabbit pab - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology anti phosphorylated nf κb p65
    OMVs upregulate tumor MHC I expression via the TLR4–NF‐κB–NLRC5 axis. (A) Relative mRNA expression of H‐2K and H‐2D in B16 cells after 24 h treatment with different OMV concentrations. (B) Representative plots for flow cytometry analysis of MHC‐I⁺ B16 tumor cell. (C) Proportions of MHC I + B16 cells after indicated treatments. (D) Volcano plot of differentially expressed genes in OMV versus control groups (red: significantly upregulated ≥2‐fold; blue: significantly downregulated ≥2‐fold). (E) GO enrichment of upregulated genes. (F) KEGG pathway enrichment of genes associated with innate and adaptive immune responses. (G‐H) Heat maps of MHC I–related genes detected by RNA‐seq (G) and qPCR (H). (I) Western blot analysis of TLR4 (≈100 kDa), <t>p‐p65</t> (≈70 kDa), NLRC5 (≈225 kDa), and β‐actin (≈48 kDa) in tumor cells. (J) Proportions of MHC I + tumor cells after indicated treatments. (K) Proposed mechanism of OMV‐induced MHC I upregulation through the TLR–NF‐κB–NLRC5 pathway. Created in BioRender. Zhang, F. (2026) https://BioRender.com/97sw6s6 . Data are mean ± SD (n = 3). Statistical significance was determined using Student's t‐test or One‐way ANOVA. **** p < 0.0001.
    Anti Phosphorylated Nf κb P65, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+nf%CE%BAb+p65/p-NF%CE%BAB+p65+Antibody/pm41925851-89-15-20
    Average 96 stars, based on 1 article reviews
    anti phosphorylated nf κb p65 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology anti p nf κb p65
    OMVs upregulate tumor MHC I expression via the TLR4–NF‐κB–NLRC5 axis. (A) Relative mRNA expression of H‐2K and H‐2D in B16 cells after 24 h treatment with different OMV concentrations. (B) Representative plots for flow cytometry analysis of MHC‐I⁺ B16 tumor cell. (C) Proportions of MHC I + B16 cells after indicated treatments. (D) Volcano plot of differentially expressed genes in OMV versus control groups (red: significantly upregulated ≥2‐fold; blue: significantly downregulated ≥2‐fold). (E) GO enrichment of upregulated genes. (F) KEGG pathway enrichment of genes associated with innate and adaptive immune responses. (G‐H) Heat maps of MHC I–related genes detected by RNA‐seq (G) and qPCR (H). (I) Western blot analysis of TLR4 (≈100 kDa), <t>p‐p65</t> (≈70 kDa), NLRC5 (≈225 kDa), and β‐actin (≈48 kDa) in tumor cells. (J) Proportions of MHC I + tumor cells after indicated treatments. (K) Proposed mechanism of OMV‐induced MHC I upregulation through the TLR–NF‐κB–NLRC5 pathway. Created in BioRender. Zhang, F. (2026) https://BioRender.com/97sw6s6 . Data are mean ± SD (n = 3). Statistical significance was determined using Student's t‐test or One‐way ANOVA. **** p < 0.0001.
    Anti P Nf κb P65, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+nf%CE%BAb+p65/p-NF%CE%BAB+p65+Antibody/10__1096_slash_fj__202504376r-50-137-145
    Average 96 stars, based on 1 article reviews
    anti p nf κb p65 - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc p nfκb p65
    OMVs upregulate tumor MHC I expression via the TLR4–NF‐κB–NLRC5 axis. (A) Relative mRNA expression of H‐2K and H‐2D in B16 cells after 24 h treatment with different OMV concentrations. (B) Representative plots for flow cytometry analysis of MHC‐I⁺ B16 tumor cell. (C) Proportions of MHC I + B16 cells after indicated treatments. (D) Volcano plot of differentially expressed genes in OMV versus control groups (red: significantly upregulated ≥2‐fold; blue: significantly downregulated ≥2‐fold). (E) GO enrichment of upregulated genes. (F) KEGG pathway enrichment of genes associated with innate and adaptive immune responses. (G‐H) Heat maps of MHC I–related genes detected by RNA‐seq (G) and qPCR (H). (I) Western blot analysis of TLR4 (≈100 kDa), <t>p‐p65</t> (≈70 kDa), NLRC5 (≈225 kDa), and β‐actin (≈48 kDa) in tumor cells. (J) Proportions of MHC I + tumor cells after indicated treatments. (K) Proposed mechanism of OMV‐induced MHC I upregulation through the TLR–NF‐κB–NLRC5 pathway. Created in BioRender. Zhang, F. (2026) https://BioRender.com/97sw6s6 . Data are mean ± SD (n = 3). Statistical significance was determined using Student's t‐test or One‐way ANOVA. **** p < 0.0001.
    P Nfκb P65, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p+nf%CE%BAb+p65/pm41859944-99-9-15
    Average 86 stars, based on 1 article reviews
    p nfκb p65 - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    Image Search Results


    OMVs upregulate tumor MHC I expression via the TLR4–NF‐κB–NLRC5 axis. (A) Relative mRNA expression of H‐2K and H‐2D in B16 cells after 24 h treatment with different OMV concentrations. (B) Representative plots for flow cytometry analysis of MHC‐I⁺ B16 tumor cell. (C) Proportions of MHC I + B16 cells after indicated treatments. (D) Volcano plot of differentially expressed genes in OMV versus control groups (red: significantly upregulated ≥2‐fold; blue: significantly downregulated ≥2‐fold). (E) GO enrichment of upregulated genes. (F) KEGG pathway enrichment of genes associated with innate and adaptive immune responses. (G‐H) Heat maps of MHC I–related genes detected by RNA‐seq (G) and qPCR (H). (I) Western blot analysis of TLR4 (≈100 kDa), p‐p65 (≈70 kDa), NLRC5 (≈225 kDa), and β‐actin (≈48 kDa) in tumor cells. (J) Proportions of MHC I + tumor cells after indicated treatments. (K) Proposed mechanism of OMV‐induced MHC I upregulation through the TLR–NF‐κB–NLRC5 pathway. Created in BioRender. Zhang, F. (2026) https://BioRender.com/97sw6s6 . Data are mean ± SD (n = 3). Statistical significance was determined using Student's t‐test or One‐way ANOVA. **** p < 0.0001.

    Journal: Advanced Science

    Article Title: Intratumoral Fusogenic Outer Membrane Vesicles Enhance Antitumor Immunity Through Tumor MHC‐I Upregulation and Tumor Bacterization

    doi: 10.1002/advs.78279

    Figure Lengend Snippet: OMVs upregulate tumor MHC I expression via the TLR4–NF‐κB–NLRC5 axis. (A) Relative mRNA expression of H‐2K and H‐2D in B16 cells after 24 h treatment with different OMV concentrations. (B) Representative plots for flow cytometry analysis of MHC‐I⁺ B16 tumor cell. (C) Proportions of MHC I + B16 cells after indicated treatments. (D) Volcano plot of differentially expressed genes in OMV versus control groups (red: significantly upregulated ≥2‐fold; blue: significantly downregulated ≥2‐fold). (E) GO enrichment of upregulated genes. (F) KEGG pathway enrichment of genes associated with innate and adaptive immune responses. (G‐H) Heat maps of MHC I–related genes detected by RNA‐seq (G) and qPCR (H). (I) Western blot analysis of TLR4 (≈100 kDa), p‐p65 (≈70 kDa), NLRC5 (≈225 kDa), and β‐actin (≈48 kDa) in tumor cells. (J) Proportions of MHC I + tumor cells after indicated treatments. (K) Proposed mechanism of OMV‐induced MHC I upregulation through the TLR–NF‐κB–NLRC5 pathway. Created in BioRender. Zhang, F. (2026) https://BioRender.com/97sw6s6 . Data are mean ± SD (n = 3). Statistical significance was determined using Student's t‐test or One‐way ANOVA. **** p < 0.0001.

    Article Snippet: AF647‐conjugated anti‐Escherichia coli LPS antibody (Cat. No. bs‐8000R‐AF647), anti‐NFκB p65 (p‐S536) antibody (Cat. No. bs‐0982R), and anti‐Hexokinase 2 antibody (Cat. No. bs‐9455R) were obtained from Bioss (China).

    Techniques: Expressing, Flow Cytometry, Analysis, Control, RNA Sequencing, Western Blot